RE: Alva + Subcontract Model19 Feb 2022 08:47
Hi Marik
Good post, asks questions.
Personally I support the sale of Alva, it secures the 150 jobs, Orient Gene will hope to continue to secure Government Contracts off the back of having a Turnkey manufacturing plant in Scotland, albeit the mass production will be in China as they can produce for a fraction of the price of the U.K. we can guess Alva will be used for wrapping - which is what Omega were doing for OG over the summer
Omega test failed at PD for whatever reason and it’s likely they were never going to resubmit - separate subject why but we are where we are so to speak
Then we look at the buffer / reagent within the Omega LFT test, it’s not theirs it’s Mologic’s.
Omega had no real choice but to sell, they have no CTDA for what that’s worth until next Autumn? No Porton Down , USA ? Looks tricky and they need money? They have EUHUA that’s the one positive but not contracts of note - if they had contracts they would have announced ?
All in the BoD had to sell Alva in their current position
They now have £4.5M of cash , they tell us they need £3.5M working capital and they are investing £400,000 into our remaining asset in Cambridge
As such we the current shareholder don’t need an additional 100M shares @ 5p - how we got this placing is another discussion
The BoD have authority to create /sell 10% new shares, when this placing fails - which it will - they should place
18M shares and offer to existing shareholders first, they may get away at 7p, no fees of note (avoid the £400,000)
They then have £5.5M plus in the Bank
Loss making division gone
£12M a year profitable division - @ 50% gross
The ‘ rub’ is we don’t want / need 330,000,000 shares and the BoD need more skin in the game and consider their personal remuneration which is out of sync with a business generating £12M a year of sales
The NO vote puts them on notice they need to start ‘reading the room’ it’s not all about them and their £200,000 salaries / options